BDTX Stock Price
Black Diamond Therapeutics, Inc.
BDTX stock price is $1.70 (+1.19% on the day), giving Black Diamond Therapeutics, Inc. a market cap of $97.67M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
BDTX Stock Overview
- Price
- $1.70
- Previous close
- $1.68
- Open
- $1.67
- Market cap
- $97.67M
- P/E ratio
- 4.4
- 52-week range
- $1.60 - $4.94
- 1-year price target
- $9.06
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 43
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BDTX | $1.70 | +1.2% | 1.07M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Black Diamond Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW